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Abstract
Background: Angiotensinogen (AGT) enzyme comprises a vital module of RAAS system that effectively controls the
blood pressure and related cardiovascular functions. Ample association studies have reported the importance of AGT
variants in cardiovascular and non-cardiovascular adversities. But lately, owing to the complexity of the many anomalies,
the haplotype based examination of genetic variation that facilitates the identification of polymorphic sites which are
located in the vicinity of the causative polymorphic site, gets greater appreciation.
Methods: In the present study, we have done genotype and haplotype analysis of AGT gene in reference to
hypertension to confirm the association of the two in an Indian population. To accomplish this, we performed
candidate SNPs analysis and construct possible haplotypes across the AGT promoter and gene region in 414 subjects
(256 Hypertensive cases and 158 controls).
Results: We found four SNPs (rs11568020: A-152G and rs5050: A-20C in promoter; rs4762 and rs699 in exon2)
and 3 haplotypes (H4, H7 and H8) that showed a stronger positive association with hypertension. The haplotype H2 was
showing protective association with hypertension.
Conclusion: The results of the present study confirmed and reestablished the role of AGT gene variants and
their haplotypes in the causation of hypertension in Indian population and showed that haplotypes can provide stronger
evidence of association.
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Background
Hypertension (HTN) is a chronic medical condition in
which the blood pressure in the arteries is increased. It is
one of the most common and complex human diseases
that cause significant heart failure, renal failure, ventricu-
lar arrhythmias, blindness and other serious medical prob-
lems [1, 2]. It is a common risk factor for cardiovascular
morbidities like stroke, atherosclerosis and myocardial in-
farction. In a worldwide analysis of the global problem of
HTN, 20.6% of Indian men and 20.9% of Indian women
were suffering from HTN in 2005 [3, 4]. This problem of
HTN is going to worsen in the near future as the rates for
HTN are projected to go up to 22.9 and 23.6% in Indian
men and women by 2025 [4].
As the blood pressure is regulated by the surrounding
environment and also by the genetics of individuals, the
genetic basis of primary hypertension became complex
due to the interaction of the two. For a complex trait the
susceptible gene(s) are searched by genetic-association
studies. These studies look for deviations from the ran-
dom occurrence of the alleles with respect to disease
phenotype which consequently results in significant in-
crease or decrease in their frequency. Allelic association
can explain either by direct biological action of the allele
(SNP analysis) or by linkage disequilibrium (LD) with a
nearby susceptibility gene (haplotype analysis). SNP ana-
lysis is pretty widely used for the disorder with single
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gene origin. However the complex nature of disorder
renders the exact genetic cause in assumptive associ-
ation and increases the complexity of understanding. For
such complex traits, recently the LD based examination
of genetic variation (haplotype analysis) that facilitates
the identification of polymorphic sites which are located
in the vicinity of the causative polymorphic site, gets
greater appreciation [1, 5]. LD occurs when a particular
marker allele lies so close to the disease-susceptibility al-
lele that these alleles will be inherited together over
many generations [6].
Among candidate genes for primary hypertension, AGT
was the first and one of the most examined genes associ-
ated with it [7]. The human AGT gene is a member of the
serpin gene superfamily, which extends only 12 kb with 5
exons on chromosome 1 (1q42-q43). It is equally diverse
in its cell specificity as it expressed in multiple tissues, in-
cluding the liver, adipose tissue, heart, vessel wall, brain,
and kidney [8]. Functionally, AGT act as a substrate to
rennin enzyme, a part of Renin-Angiotensin-Aldosterone
System (RAAS), where N-terminal amino acids of mature
AGT secreted by hepatocytes are cleaved intravascular.
First cleaved by renin, released from juxtaglomerular cells,
to yield the angiotensin-I decapeptide, and then by angio-
tensin converting enzyme (ACE) to generate the angioten-
sin II (Ang II) octapeptide. The renin–AGT enzymatic
reaction is the rate-limiting step of the RAAS cascade
which controls the plasma AGT levels and crucial for
maintaining blood pressure [7].
The most convincing early genetic evidence implicat-
ing this gene in essential hypertension in humans has re-
vealed a number of polymorphisms in the 5′ flanking
region, exons, and introns of the gene [7]. Zhao et al.,
also showed the functional implication of nucleotides
−20, −17, −517, and −792 of AGT in the pathogenesis of
high blood pressure [9]. Several other studies pointed
out a correlation of plasma AGT levels, anti-AGT anti-
bodies, injection of AGT and AGT transgenes with
blood pressure [10–13]. All these studies laid foundation
and make AGT gene a perfect marker to study its haplo-
type association with the pathogenesis of hypertension.
In this context, a study identified 44 SNPs in the AGT
gene and assembled a complete haplotype map with six
major haplotypes of AGT from whites and Japanese
which accounts for most of the variation in the AGT gene,
although the frequency of each differed substantially in
the two populations [14]. Further, Zhu et al., also con-
structed a haplotype map of each gene of the RAAS in
black and white hypertensive populations [15, 16]. He fur-
ther performed association analysis with individual SNPs
and haplotype blocks and found a positive association
with several SNPs in AGT gene with hypertension, though
there was no transmission distortion of any particular
haplotype for AGT [15]. Contrasting results were obtained
in another report evaluating the association between
haplotype blocks of AGT and their interaction with the
ACE locus in a Taiwanese population [6]. These studies,
however, hint toward the association of haplotypes with
the hypertension, but leaving the complexity of this asso-
ciation difficult to interpret.
In the present study, we wish to provide further reso-
lution of the contribution of AGT genetic variation
(both SNPs and haplotype) to hypertension in the con-
text of Indian population. Based on the foundation laid
by earlier studies, the present study hypothesized that
the AGT genotype and haplotype will also associate
with hypertension in Indian population. Further, to the
best of our knowledge this is the first report of associ-
ation of individual SNPs and haplotype blocks of AGT
with hypertension in an Eastern Indian population.
Methods
Study patients
The present study is a cross-sectional case control study
consisted of 256 hypertensive patients and 158 controls
from the ethnic Bengali speaking population of Kolkata
city and surrounding area, West Bengal in Eastern India.
Registered patients were recruited from two participating
medical institutions, namely Calcutta Medical College and
Hospital (Kolkata, West Bengal) and B.P. Poddar Hospital
and Research Centre (Kolkata, West Bengal). Ethical com-
mittee clearance was obtained from the respective medical
institutions and Ethical committee of the Anthropological
Survey of India, Govt. of India. Prior to the recruitment of
subjects and sample collection, an informed written con-
sent was obtained from all the participants. The identifica-
tion of hypertensive patients was based on the physician’s
recommendation or registered patient for antihypertensive
drugs. Blood samples of the control group were obtained
from non-hypertensive individuals that were randomly se-
lected based on physical examinations during May to Sep-
tember 2010. For the controls, selection criteria included;
no individual history of high blood pressure, gender
matched to cases and individuals were unrelated.
Anthropometric, physiological and biochemical data
Both, patients and controls were anthropometrically
measured for height vertex (cm), and weight (kg) using
standard methodology [17, 18]. Body mass index (BMI)
was calculated using the formula, weight (kg)/[height
(m2)]. Clinical information regarding duration of dia-
betes, presence of any complication and history of other
disorders was recorded. Systolic blood pressure (SBP)
and diastolic blood pressure (DBP) were measured on
the right arm of the subjects in sitting position using an
automated blood pressure monitor (Omron, Japan) after
15 min of rest.
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Approximately 10 ml of peripheral venous blood sam-
ple was collected from each individual participated in
the study into two separate tubes, one in a 6 ml BD K2
vacutainer® (BD, NJ, USA) containing EDTA as an anti-
coagulant for genetic analysis and another in a 4 ml BD
Serum vacutainer® without EDTA for biochemical ana-
lysis. Blood samples were stored at 4 °C to avoid haem-
olysis and cellular damage. Samples were transported to
the laboratory within 3 h of collection to ensure good re-
sults. Thereafter, blood samples were transferred to la-
beled sterile polypropylene centrifuge tubes. The blood
samples were centrifuged and serum was separated and
stored at 4 °C as well as at −86 °C until further analysis.
Blood glucose was measured using the Breez 2 glucometer
(blood glucose monitor) in the field itself. All laboratory
tests were conducted at the DNA laboratory in the An-
thropological Survey of India. The levels of total choles-
terol, triglycerides, high-density lipoprotein cholesterol
(HDL), low density lipoprotein cholesterol (LDL), urea,
uric acid, creatinine, chloride, total protein and albumin in
serum were measured enzymatically on an auto analyzer
EM360 (TRANSASIA) with the help of kits supplied by
Transasia Bio-Medical LTD for the purpose. Genomic
DNA was prepared from fresh whole blood sample col-
lected in EDTA containing tube by using the conventional
phenol-chloroform extraction method followed by ethanol
precipitation [19] and the DNA quantity and quality was
checked by both spectrophotomery and agarose gel elec-
trophoresis. The DNA samples were stored at −20 °C to
−80 °C as per the period of usage.
Genotyping
For the present study, our region of interest was the 5’
UTR, exon, and intron region of AGT gene. Therefore,
the study included Nine SNPs (rs5046 (5'UTR), rs5049
(5'UTR), rs11568020 (5'UTR), rs5050 (5'UTR), rs5051
(5'UTR), rs2148582 (intron), rs3789679 (intron), rs4762
(exon 2), rs699 (exon 2), searched through the Ensemble
genome browser, NCBI SNPs database and the HapMap
database (Fig. 1). In this present study, except self de-
signed AGT PRO primer, previously published primers
were used for the PCR based detections of SNPs [14, 20].
Only those PCR products that had a single amplification
product with no evidence of non-specific amplification
were used for DNA sequencing. The samples were
analyzed on ABI 3730 genetic analyzer with a 48 capillary
(Applied Biosystems, USA) to generate DNA sequences.
After completion of sequencing reaction, the generated
sequences were checked by using Sequencing Analysis v5.2
software (Applied Biosystems, USA), and sequences were
aligned to their respective reference sequences with the use
of SeqScape v2.5 software (Applied Biosystems, USA), for
automated sequence data analysis. It performs sequence
comparisons for variant identifications, SNP discovery and
validation. Haplotype construction was done using Haplo-
view 4.2 software [21]. A total of 13 possible haplotypes
(H1 to H13) was constructed for association analysis.
Statistical analysis
Descriptive statistics were calculated for all the an-
thropometric and clinical variables. Mean differences
Fig. 1 Schematic map of angiotensinogen (AGT) gene. Structure of the human AGT gene with common SNPs depicted from the promoter, Intron
and Exon 2 regions. Known transcription factor binding sites and Methylation site overlying SNPs are shown below the corresponding SNP. Putative
transcription factor binding sites and Haplotypes are in parentheses. UTR indicates untranslated region [1, 5, 28, 29, 38]
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between case and control groups for the continuous var-
iables were calculated using t- test. A level of p < 0.05
was assumed as statistically significant. All the above
analyses were performed using SPSS v.16 software (SPSS
Inc., Chicago, IL, USA). Allele frequencies were calcu-
lated for the SNPs and tested for Hardy-Weinberg equi-
librium (HWE) and allelic association with disease
(Fisher exact test) using PLINK software package [22].
Genotype association with the phenotypes was tested
under different genetic models by regression analysis.
For comparing the allelic distributions between study
groups, the odds ratio (OR) with 95% confidence interval
(CI) were also calculated. Haploview 4.2 software was
used to evaluate LD and construct haplotypes [21]. Hap-
lotypes were constructed from genotype data in the full-
size case–control panel within blocks to find their asso-
ciation with hypertension risk using an EM algorithm
method with Haploview 4.2 software. LD between the
nine SNPs used in haplotype analysis was measured by a
pairwise D' statistic. The structure of the LD block (with
80% CI) was examined using the solid spine and custom
methods in LD analysis Haploview 4.2 software [21, 23].
Results
Subject’s characteristics
As per the disease, the descriptive statistics of metric
variables were shown in Table 1. Comparatively, the
mean age, blood pressure, LDL, Uric acid, Urea, BUN,
chloride, glucose and cholesterol in Hypertensive group
were significantly higher than Normotensive group. On
the other hand, higher values of BMI, triglyceride and
HDL have also been found among the Hypertensives but
statistically non-significant.
Association analyses of AGT polymorphism and
hypertension
All the SNPs were polymorphic with minor allele frequen-
cies > 5% and genotype distributions in agreement with
Hardy-Weinberg equilibrium among the Normotensive
control group (Table 2). Two of the SNPs rs699 and
rs4762 were non-synonymous mutations, the rest SNPs
were in the untranslated regions or intron of the gene
(Additional file 1: Table S1). The association analysis of
hypertension (256 cases versus 158 controls) demonstrated
the causative associations of rs11568020 A [Odds ratio
(OR) = 6.382; p-value (p) = 0.003], the rs5050 C [OR =
2.808; p = 0.000] and the rs4762 T [OR =1.57; p = 0.034]
variants with the disease (Table 3).
The associations were further verified via regression ana-
lysis through 3 genotypic model tests; additive model
(ADD), dominant model (DOM) and recessive model
(REC) to confirm the predictive association between both
study groups. ADD and DOM models showed significant
association with hypertension for the SNP rs11568020
(ADD: OR = 6.61, p = 0.012; DOM: OR = 6.61, P =0.012)
and rs4762 (ADD: OR = 1.587, p = 0.032), while the reces-
sive model shows significant association and risk with the
hypertension for the SNP rs699 (OR = 2.303; p = 0.04417).
The SNP rs5050 is showing association with hypertension
in all three genotypic models (ADD: OR = 2.339, p = 0.000;
DOM: OR = 2.661, p = 0.000 and REC: OR = 5.896; p =
0.001) (Table 4).
Association analyses of AGT gene haplotypes and
hypertension
Haplotype analysis involves different combinations of
the nine studied SNPs, employing the most prevalent 9-
mer sequence H1: CGGAGTCCT (frequency = 0.211;
Case = 0.201; Control = 0.229; p = 0.330) as reference for
comparative analysis of their relationships with hyper-
tension risk. As shown in Table 5, the haplotypes H4:
CGGCACCTC (χ2 = 7.234; p = 0.007), H7: CGGCGTCC
T (χ2 = 11.887; p = 0.001) as well as haplotype H8: CGA-
CACCCC (χ2 = 5.557; p = 0.018) constructed from all
the nine SNPs were significantly associated with HTN
and exhibit the causative risk for the disease. Besides
this, haplotype H2: CGGAACCCC (χ2 = 7.718; p = 0.005)
was associated with protective effect and showed protec-
tion against HTN.
Further, the associations trickled down to the shorter se-
quences through the solid spine analysis method where all
the SNPs formed three Block (Fig. 2b). Block 1 consisted
of the SNPs rs5046 and rs5049, while rs11568020 and
rs5050 form Block 2. The rest of the SNPs (rs5051,
rs2148582, rs3789679, rs4762, rs699) were constituted of







Mean SE Mean SE
Age (YEAR) 53.03 0.41 56.45 0.51 0.000
Body Mass Index
(BMI) (Kg/m2)
23.45 0.31 24.22 0.28 0.075
SBP (mm of mercury) 105.37 0.61 161.38 1.08 0.000
DBP (mm of mercury) 75.51 0.67 91.98 0.74 0.000
Glucose(mg/dl) 120.77 3.71 132.50 3.70 0.035
Cholesterol (mg/dl) 167.19 2.75 177.82 2.70 0.009
Triglycerides (mg/dl) 153.38 5.81 162.83 5.08 0.233
HDL (mg/dl) 45.73 1.40 47.71 1.07 0.259
LDL (mg/dl) 90.79 1.94 97.66 2.03 0.022
Uric Acid (mg/dl) 5.48 0.11 6.10 0.10 0.000
Urea(mg/dl) 22.40 1.25 46.44 2.28 0.000
BUN (mg/dl) 10.46 0.58 21.69 1.06 0.000
Chloride (mmol/L) 103.92 0.76 110.10 0.84 0.000
Significance values are italicized, Level of significance < 0.05
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block3 [Table 6]. The highest level of significant associ-
ation exhibited by Block 2 [2-mer GC (χ2 = 20.804; p
=0.000)]. Apart from the haplotype GC, a second 2-mer
AC (χ2 = 6.683; p = 0.0097) also associated with risk for
HT, while haplotype GA (χ2 = 29.741; p =0.000) was pro-
tective against HT. The Block 1 and Block 3 showed no as-
sociation between case and control groups.
Discussion
The main objective of many genetic researches is to find
out genes that are responsible for the particular disease.
The findings of these genes should illuminate the under-
standing of the disease process, so that methods for pre-
venting and treating the disease can be developed in the
best possible way. For diseases with a relatively straight-
forward genetic basis i.e. the single-gene disorders, the
current methods of genetic detection are pretty much
sufficient to find the genes involved. But the problem
arises with the genetic detection of multi-genetic disor-
ders. Many common diseases such as heart disease,
stroke, diabetes, cancers or psychiatric disorders have
complexity in their genetic control. They are
Table 2 Genotype distribution and HWE tests for all nine diallelic polymorphisms in the AGT Gene
dbSNP ID Minor Allele (A1) A2 Group Genotype Distribution HWE
GENO p-value O(HET) E(HET) p-value
rs5046 T C Hypertensive 14/90/152 0.655 0.3516 0.3547 0.861
Normotensive 12/52/94 0.3291 0.3653 0.198
rs5049 A G Hypertensive 14/94/148 0.684 0.3672 0.363 1
Normotensive 12/56/90 0.3544 0.3781 0.406
rs11568020 A G Hypertensive 0/20/236 0.004 0.07812 0.07507 1
Normotensive 0/2/156 0.01266 0.01258 1
rs5050 C A Hypertensive 34/74/148 0.000 0.2891 0.4008 0.000
Normotensive 4/30/124 0.1899 0.2116 0.244
rs5051 G A Hypertensive 28/90/138 0.292 0.3516 0.4077 0.031
Normotensive 12/66/80 0.4177 0.4074 0.846
rs2148582 T C Hypertensive 26/90/140 0.170 0.3516 0.4008 0.060
Normotensive 10/68/80 0.4304 0.4019 0.433
rs3789679 T C Hypertensive 0/50/206 * 0.1953 0.1762 0.145
Normotensive 2/24/132 0.1519 0.1615 0.342
rs4762 T C Hypertensive 8/70/178 0.000 0.2734 0.2795 0.659
Normotensive 0/36/122 0.2278 0.2019 0.224
rs699 T C Hypertensive 28/88/140 0.023 0.3438 0.4043 0.019
Normotensive 8/72/78 0.4557 0.4019 0.114
Significance values are italicized, Level of significance <0.05; Chi-Sq = 4.384; Degrees of freedom (DF) = 2; 1 cells with expected counts less than 1.0;*Chi-Square
approximation probably invalid; 2 cells with expected counts less than 5.0
Table 3 Fisher exact test for the study group Normotensive and Hypertensive
SNP Minor
allele
Frequency Odd Ratio (95% CI) p-value
Hypertensive Normotensive
rs5046 T 0.2305 0.2405 0.9458 (0.68 - 1.315) 0.736
rs5049 A 0.2383 0.2532 0.9228 (0.6668-1.277) 0.677
rs11568020 A 0.03906 0.006329 6.382 (1.482-27.49) 0.003
rs5050 C 0.2773 0.1203 2.808 (1.9-4.148) 0.000
rs5051 G 0.2852 0.2848 1.002 (0.7342-1.367) 1
rs2148582 T 0.2773 0.2785 0.9943 (0.7272-1.36) 1
rs3789679 T 0.09766 0.08861 1.113 (0.6851-1.809) 0.714
rs4762 T 0.168 0.1139 1.57 (1.034-2.383) 0.034
rs699 T 0.2812 0.2785 1.014 (0.7418-1.386) 1
Significance values are italicized, Level of significance < 0.05
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harmonized by multiple genes in coordination with en-
vironmental factors. Hence the genetic clarity in this
context appears as a hazy cloud of assumptions. Al-
though, the genetic contributions to these complex dis-
orders are not clear, many researchers still consider the
importance of common variants and follow the
Common-Disease/Common-Variant theory.
Several association studies have been reported the
importance of AGT polymorphisms and explored their
association with a variety of cardiovascular and non-
cardiovascular phenotypes [1, 24–26]. Hypertension is
one such risk phenotype of cardiovascular disorders pu-
tatively associated with AGT variants [5, 27–31]. The
results of the present study also found the role of AGT
variants in susceptibility for the risk of HTN in Indian
population which is similar with several other studies
in other ethnic groups, including Taiwanese, Mexican,
Caucasian, Chinese, Slovaks, Polish, Tunisians and Saudi
[29, 32–37]. In the present study, 6.61 fold risk of
rs11568020, 2.339 fold risk of rs5050, 1.587 fold risk of
rs4762 (in additive and Dominant model) and 2.303 fold
risk of rs699 with the occurrence of hypertension (Tables 3
and 4) suggests the role of AGT gene in hypertension. Pre-
vious studies with similar variants also showed risk associ-
ation with essential hypertension [1, 5, 27, 29, 30, 38, 39].
Therefore, our study reestablishes the place of AGT as a
risk gene for hypertension also in Indian populations.
The possible mechanistic approach which explains the
results of the present study and confirm the role of two
promoter SNPs, rs11568020 & rs5050 and two exon
SNPs rs4762 & rs699 in the causation of hypertension
gyrate around the positional significance of these associ-
ated variants in the gene. It is a well established fact that
methylation levels of genes, especially methylation of
CpG sites in promoter regions involve in control of gene
expression, epigenetically. Mopidevi et al., showed that
hAGT promoter CpG sites in the kidney are more meth-
ylated as compared to liver [40]. Hence the individual
specific variation in tissue specific pattern might be the
major cause for the occurrence of the disorders. How-
ever, the molecular mechanisms involved in tissue spe-
cific expression of this gene are not clearly understood.
But the possible explanation for this phenomenon may
be the DNA methylation pattern of the AGT promoter
region. A number of CpG dinucleotides, the targets for
DNA methylation, are located in the human AGT pro-
moter. The human AGT promoter region has four CpG
sites that correspond to the positions −218, −144, −18
and −7 (Fig. 1). The-218 CpG site of the human AGT
promoter is the binding site of CCAAT enhancer bind-
ing protein (CEBP). Dickson et al., also showed that
when the promoter at position −218/-217 is hypomethy-
lated in tissues and cells (liver, heart and HepG2 hepato-
cytes) AGT is expressed in relatively higher proportion,
but in hypermethylated condition (adrenal glands, leuko-
cytes and adrenocortical H295R cells) its expression is
lower [41]. Therefore, the methylation pattern of a CpG
dinucleotide within the CEBP-binding site appears to be
inversely associated with AGT expression. However, in
the present study the SNP near to this CpG site showed
no role in the causation of HTN suggesting no role of
methylation at this site in the Indian populations. How-
ever, in the present study rs11568020 (at position-152)
& rs5050 (at position −20) are the two nearby SNPs of
the CpG sites at −144 and −18 in the promoter region.
The association of these two SNPs with HTN hints to-
ward the control of CpG methylation on their expres-
sion. The role of SNP rs5050 (A-20C) was also found to
be crucial in DNA methylation on USF1/ESR1 binding
to the target DNA site [41, 42, 9]. Further, this site is a
binding site for most of the transcription factor of AGT
Table 4 Logistic regression analysis between Normotensive and
Hypertensive group
Test SNP A1 OR P
Additive model rs5046 T 0.948 0.745
rs5049 A 0.9241 0.631
rs11568020 A 6.61 0.011
rs5050 C 2.339 0.000
rs5051 G 1.002 0.991
rs2148582 T 0.9946 0.972
rs3789679 T 1.119 0.657
rs4762 T 1.587 0.032
rs699 T 1.013 0.932
Dominant model rs5046 T 1.005 0.981
rs5049 A 0.9658 0.865
rs11568020 A 6.61 0.011
rs5050 C 2.661 0.000
rs5051 G 0.877 0.517
rs2148582 T 0.8498 0.422
rs3789679 T 1.232 0.432
rs4762 T 1.485 0.090
rs699 T 0.8079 0.292
Recessive model rs5046 T 0.7039 0.388
rs5049 A 0.7039 0.388
rs11568020 A NA NA
rs5050 C 5.896 0.001
rs5051 G 1.494 0.265
rs2148582 T 1.673 0.183
rs3789679 T 0.000 0.999
rs4762 T 0.000 0.998
rs699 T 2.303 0.044
Significance values are italicized, Level of significance < 0.05
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Table 5 Haplotype association (Custom)
Haplotype db SNP ID Frequencies p value
rs5046 rs5049 rs11568020 rs5050 rs5051 rs2148582 rs3789679 rs4762 rs699 Hypertensive Normotensive
H1 CGGAGTCCT C G G A G T C C T 0.201 0.229 0.330
H2 CGGAACCCC C G G A A C C C C 0.153 0.230 0.005
H3 TAGAACCCC T A G A A C C C C 0.198 0.225 0.352
H4 CGGCACCTC C G G C A C C T C 0.143 0.081 0.007
H5 CGGAACTCC C G G A A C T C C 0.088 0.079 0.667
H6 CGGCACCCC C G G C A C C C C 0.021 0.011 0.269
H7 CGGCGTCCT C G G C G T C C T 0.047 0.004 0.001
H8 CGACACCCC C G A C A C C C C 0.031 0.006 0.018
H9 CGGAGTCCC C G G A G T C C C 0.015 0.026 0.297
H10 CAGAACCCC C A G A A C C C C 0.012 0.013 0.904
H11 CGGAACCTC C G G A A C C T C 0.017 0.027 0.349
H12 TAGCACCCC T A G C A C C C C 0.016 0.002 0.065
H13 CGGAACCCT C G G A A C C C T 0.019 0.026 0.545
Significance values are italicized, Level of significance < 0.05
Fig. 2 Linkage disequilibrium structure of the nine studied angiotensinogen SNPs. a Custom and b Solid Spine generated by Haploview. The
SNPs are shown sequentially as they appear on the chromosome (not to scale). The value within each square in the triangle plot represents the
pairwise correlation between SNPs (measured as D' = coefficient of linkage disequilibrium) defined by the upper left and the upper right sides of
the Squares. D' for each comparison is given as the number in the square if it is not equal to 1. The Squares without a number correspond to D' = 1. The
multiallelelic D' values over multiple blocks are shown between each block. Shading represents the magnitude and significance of pairwise LD, with a gray
to white color gradient reflecting higher to lower LD values. The frequency of each common haplotype within a block is to the right of the haplotype
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gene [1, 5], hence the methylation in nearby site controls
its expression and enhances the adversities associated with
the AGT gene (in present context HTN). It is anticipated
that the association of SNP rs11568020 (nearby the CpG
site −144) with HTN may also show the similar pattern of
mechanistic effect as shown by SNP rs5050 (A-20C). How-
ever, in the present study nearby sequence analysis of this
position does not support the epigenetic modulation the-
ory by DNA methylation. May be some other mechanism
exist for this SNP association with essential hypertension.
However to the best of our knowledge, no studies have
been done regarding DNA-protein interaction in the SNP
rs11568020 at position -152A/G. Future studies in Indian
populations may be done to illuminate in this regard.
Haplotype analysis is a powerful tool for identifying can-
didate genes for complex trait disease. The haplotype ana-
lysis of the nine variants of AGT considered in the present
study showed contrasting haplotype profiles of hyperten-
sive and normotensive with significant difference between
the two (Tables 5 and 6). Haplotype analyses of the AGT
gene and its association with hypertension have also been
reported in whites and Japanese [27, 43]. Jeunemaitre et
al., have shown that ancestral T235/A-6 haplotype was as-
sociated with hypertension [27]. Sato et al., also identified
8 SNPs and demonstrated that only M235/G-6 haplotype
was significantly associated with a hypotensive effect [43].
In Indian context, similar finding was reported by Patnaik
et al. in 2015 [44]. The results of the present study
confirmed the associations of AGT gene haplotype in
Indian population as three haplotypes; haplotypes H4:
CGGCACCTC H7: CGGCGTCCT and haplotype H8:
CGACACCCC, were significantly associated with HTN
and exhibit the causative risk for the disease (p-value
<0.001). Haplotype H4 consist of two mutant alleles
(rs5050C and rs4762T) one from promoter region and one
from Exon respectively. Haplotype H7 consists of four mu-
tant alleles (rs5050C, rs5051G, rs2148582T and rs699T)
two are from the promoter and two are from exon respect-
ively. Similar to H4 haplotype H8 haplotype is consists of
two mutant alleles (rs5050C and rs11568020A), but both
are from promoter region. One interesting observation
about these positively associated haplotypes is that they all
have a common SNPs rs5050. The involvement of rs5050
in haplotypes suggests that its role in linkage is much dee-
per as we saw in the individual SNPs association (Table 3).
Hence the role of rs5050 (at position −20) with HTN is
further confirmed even more strongly with haplotype
analysis in the present study suggesting the importance of
haplotype analysis method in genetic variant analysis in
multi-gene anomalies. Besides this, haplotype H2:
CGGAACCCC consist of all wild type alleles, was signifi-
cantly associated with Normotensive and showed a pro-
tective effect (p-value < 0.05). In the Indian context (more
specifically Eastern Indians) this haplotype can be consid-
ered as ancestral haplotype of AGT.
Further, Tracking the shorter haplotypes down to the
2-mers e. g. Block 2, (Fig. 2b) indicates clearly that A al-
lele of rs11568020 and C allele of rs5050 were consist-
ently associated with causative effects, while its
complementary rs11568020 G allele and rs5050 A allele
consistently mediates protective actions. Both the SNPs
are situated at the core promoter region of the AGT
gene and therefore pointing the role of these loci as a
central component linking AGT with Hypertension. This
association might be regulated via the methylation pat-
tern of AGT gene.
Conclusion
The identification of associated genes in the causation of
complex disorders is very difficult and even more complex
process. Over the past few decades, tremendous efforts
have been made to solve the complexity of disorders like
hypertension. The association of SNPs and their haplo-
types with hypertension in world populations showed
some promising results in solving this problem to some
extent. The association of AGT SNPs and haplotype with
HTN in the present study confirmed the role of AGT in
HTN in Indian population. Further, the central role of
AGT rs5050 SNP in the causation of HTN in the present
study showed even more strong evidence for the import-
ance of haplotype analysis. The present study also pointed
out the possible role of methylation pattern and its inter-
action with SNPs in the promoter region of AGT in the
causation of hypertension. However, more haplotype
based and in depth studies are needed for the identifica-
tion of genetic variants in complex disorders. Future stud-
ies with defined experimental models, where the
interaction between genetic and environmental risk fac-
tors will consider, might help in this context.
Table 6 Haplotype association (Solid Spine)
Block Haplotype Freq. Frequencies p value
Hypertensive Normotensive
Block 1 CG 0.751 0.758 0.740 0.575
TA 0.229 0.226 0.234 0.8
CA 0.015 0.012 0.019 0.396
Block 2 GA 0.78 0.718 0.880 0.000
GC 0.194 0.243 0.114 0.000
AC 0.024 0.034 0.006 0.009
Block 3 ACCCC 0.453 0.435 0.482 0.18
GTCCT 0.247 0.248 0.244 0.901
ACCTC 0.141 0.159 0.112 0.061
ACTCC 0.094 0.098 0.089 0.665
ACCCT 0.025 0.024 0.026 0.852
GTCCC 0.022 0.020 0.026 0.571
Significance values are italicized, Level of significance < 0.05
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Abbreviation
A1: Code for allele 1 (the more rare or ‘minor’ allele based on the entire
sample frequencies); A2: Code for allele 2 (the more common or ‘major’
allele); ACE: Angiotensin converting enzyme; ADD: Additive model;
AGT: Angiotensinogen; Ang II: Angiotensin II; BMI: Body mass index;
BUN: Blood urea nitrogen; CEBP: Enhancer binding protein; CI: Confidence
interval; CpG: Cytosine-guanine dinucleotides; DBP: Diastolic blood pressure;
DOM: Dominant model; E(HET): Expected frequency of heterozygotes;
GENO: Genotype; hAGT: Human AGT; HDL: High-density lipoprotein cholesterol;
HTN: Hypertension; HWE: Hardy-Weinberg equilibrium; LD: Linkage
disequilibrium; LDL: Low density lipoprotein cholesterol; NCBI: National
Centre for Biotechnology Information; O(HET): Observed frequency of
heterozygotes; OR: Odds ratio; p: The asymptotic p-value for chi-square test;
PCR: Polymerase chain reaction; RAAS: Renin-angiotensin-aldosterone system;
REC: Recessive model; rs: Reference SNP ID number; SBP: Systolic blood
pressure; SNP: Single nucleotide polymorphism; UTR: Untranslated regions
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